Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSF
Dates
study started
estimated completion
Principal Investigator
by Ankit Sarin, MD (ucsf)
Headshot of Ankit Sarin
Ankit Sarin

Description

Summary

Currently a multiport robotic surgery platform (Intuitive Xi) is widely available and used for colorectal surgery indications. A Single port platform (Intuitive SP) is FDA approved for Head and Neck and Urology but has not been widely used in colorectal surgery. This study seeks to evaluate the safe and effective use of the SP platform for colorectal surgery indications.

Details

This is a single center, prospective, open-label, investigator initiated, non-randomized, interventional case-control study where researchers will study colorectal surgical procedures done using the novel Single Port (SP) Robotic Platform and compare perioperative outcomes to colorectal surgical cases done using the traditional Multi-port (Xi) Robotic Platform. AIM 1 To assess the feasibility and safety/quality of a SP platform for transabdominal and transanal colorectal operations which are currently done using multiport robotic platforms. AIM 2 To evaluate safety and quality outcomes post SP surgery in comparison with contemporaneous standard multiport Xi platform procedures.

Keywords

Colo-rectal Cancer Rectal Prolapse Colostomy Stoma Colorectal Disorders robotic surgery colorectal surgery single port Intuitive SP platform Prolapse Single port robotic colorectal surgical procedure

Eligibility

You can join if…

Open to people ages 18 years and up

  • The subject is male or female, greater than or equal to 18 years of age. If female, the subject has a negative urine pregnancy test and is not lactating, or has not been of childbearing potential for at least 3 months prior to use of study product. To be considered to be not of childbearing potential, the subject must be postmenopausal for at least 2 years; have had a hysterectomy or bilateral tubal ligation, or be proven to be otherwise incapable of pregnancy. If of childbearing potential, the subject must have been practicing one of the following methods of contraception consistently for at least 1 month prior to study entry and agree to continue practicing it during the study: hormonal contraceptives, intrauterine device, spermicide and barrier, spouse/partner sterility; or is practicing abstinence and agrees to continue abstinence or to start an acceptable method of contraception from the above list if sexual activity commences.
  • There is documentation of a colorectal diagnosis requiring operative interventions with clinical plans for a robotic operation.
  • For robotic transanal procedures, patients who would meet standard guidelines for a transanal procedures (T1N0 rectal adenocarcinoma, Precancerous adenomas, and localized neuroendocrine tumors) distal to 15 cm from the anal verge.
  • The subject is in good general health as evidenced by medical history and physical examination
  • The subject is able and willing to provide written informed consent.
  • The subject agrees to comply with the requirements of the protocol and complete study measures.
  • The subject has stable residence and telephone.

You CAN'T join if...

  • The subject is child less than 18 years of age
  • The subject is a female who is pregnant or lactating
  • The subject falls under the American Society of Anesthesia Class IV (Patients with severe systemic disease that is a constant threat to life).
  • The subject falls under American Society of Anesthesia Class V (Moribund patients who is not expected to survive without the operation)
  • The subject has a history of clinically significant renal, hepatic, neurological, cardiac or chronic pulmonary disease that in the judgment of the investigator precludes participation.
  • The subject has advanced/ Stage IV cancer
  • The subject has received neo-adjuvant chemotherapy or radiation therapy
  • The subject requires an emergency operation.
  • The subject is unable to fully comprehend or consent to the study
  • The subject is unwilling to be available for follow-up assessments.

Location

  • UCSF Medical Center at Mission Bay accepting new patients
    San Francisco California 94158 United States

Lead Scientist at UC Cancer

  • Ankit Sarin, MD (ucsf)
    Associate Professor, Surgery, School of Medicine. Authored (or co-authored) 33 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Ankit Sarin, MD, MHA
ID
NCT05321134
Study Type
Interventional
Participants
Expecting 25 study participants
Last Updated